These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21056131)

  • 1. Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro.
    Mannal P; McDonald D; McFadden D
    Am J Surg; 2010 Nov; 200(5):577-80. PubMed ID: 21056131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pterostilbene inhibits breast cancer in vitro through mitochondrial depolarization and induction of caspase-dependent apoptosis.
    Alosi JA; McDonald DE; Schneider JS; Privette AR; McFadden DW
    J Surg Res; 2010 Jun; 161(2):195-201. PubMed ID: 20031172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen and tranilast show a synergistic effect against breast cancer in vitro.
    Darakhshan S; Ghanbari A; Gholami Rad F; Bidmeshki Pour A
    Bratisl Lek Listy; 2015; 116(1):69-73. PubMed ID: 25666966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of (-)-epigallocatechin-3-gallate and pterostilbene on pancreatic cancer growth in vitro.
    Kostin SF; McDonald DE; McFadden DW
    J Surg Res; 2012 Oct; 177(2):255-62. PubMed ID: 22583593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment.
    Marcsek Z; Kocsis Z; Jakab M; Szende B; Tompa A
    Cancer Biother Radiopharm; 2004 Dec; 19(6):746-53. PubMed ID: 15665622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
    Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
    J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pterostilbene on melanoma alone and in synergy with inositol hexaphosphate.
    Schneider JG; Alosi JA; McDonald DE; McFadden DW
    Am J Surg; 2009 Nov; 198(5):679-84. PubMed ID: 19887199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O; Wackwitz B; Haus U; Ortmann O
    Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pterostilbene inhibits lung cancer through induction of apoptosis.
    Schneider JG; Alosi JA; McDonald DE; McFadden DW
    J Surg Res; 2010 Jun; 161(1):18-22. PubMed ID: 20031166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen in early breast cancer.
    Bryce CJ
    Lancet; 1998 Aug; 352(9125):403. PubMed ID: 9717952
    [No Abstract]   [Full Text] [Related]  

  • 13. Estrogen dependent growth inhibitory effects of tamoxifen but not genistein in solid tumors derived from estrogen receptor positive (ER+) primary breast carcinoma MCF7: single agent and novel combined treatment approaches.
    Nobert GS; Kraak MM; Crawford S
    Bull Cancer; 2006 Jul; 93(7):E59-66. PubMed ID: 16873071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
    J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
    Kim R; Tanabe K; Emi M; Uchida Y; Toge T
    Cancer; 2005 May; 103(10):2199-207. PubMed ID: 15830342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen.
    Cameron DA; Ritchie AA; Miller WR
    Eur J Cancer; 2001 Aug; 37(12):1545-53. PubMed ID: 11506964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
    Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
    Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
    Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
    Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pterostilbene inhibits pancreatic cancer in vitro.
    Mannal PW; Alosi JA; Schneider JG; McDonald DE; McFadden DW
    J Gastrointest Surg; 2010 May; 14(5):873-9. PubMed ID: 20140535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.